|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Bristol-Myers Squibb Otsuka America Pharmaceutical |
| Information provided by: | Bristol-Myers Squibb |
| ClinicalTrials.gov Identifier: | NCT00036361 |
Purpose
The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
| Condition | Intervention | Phase |
|
Schizophrenia Schizoaffective Disorder |
Drug: Aripiprazole |
Phase III |
| MedlinePlus related topics: | Schizophrenia |
| Drug Information available for: | Aripiprazole |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety Study |
| Official Title: | Broad Effectiveness: Study With Aripiprazole |
Eligibility
| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations
More Information
BMS Clinical Trials Disclosure 
  |
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm 
  |
| Study ID Numbers: | CN138-087 |
| First Received: | May 8, 2002 |
| Last Updated: | June 27, 2008 |
| ClinicalTrials.gov Identifier: | NCT00036361 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|